Data di Pubblicazione:
2024
Abstract:
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood. Here, we identify, via two in vitro genome-wide CRISPR screens probing Daratumumab resistance, KDM6A as an important regulator of sensitivity to Daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC). Loss of KDM6A leads to increased levels of H3K27me3 on the promoter of CD38, resulting in a marked downregulation in CD38 expression, which may cause resistance to Daratumumab-mediated ADCC. Re-introducing CD38 does not reverse Daratumumab-mediated ADCC fully, which suggests that additional KDM6A targets, including CD48 which is also downregulated upon KDM6A loss, contribute to Daratumumab-mediated ADCC. Inhibition of H3K27me3 with an EZH2 inhibitor resulted in CD38 and CD48 upregulation and restored sensitivity to Daratumumab. These findings suggest KDM6A loss as a mechanism of Daratumumab resistance and lay down the proof of principle for the therapeutic application of EZH2 inhibitors, one of which is already FDA-approved, in improving MM responsiveness to Daratumumab.
Tipologia CRIS:
03A-Articolo su Rivista
Elenco autori:
Liu J.; Xing L.; Li J.; Wen K.; Liu N.; Liu Y.; Wu G.; Wang S.; Ogiya D.; Song T.-Y.; Kurata K.; Penailillo J.; Morelli E.; Wang T.; Hong X.; Gulla A.; Tai Y.-T.; Munshi N.; Richardson P.; Carrasco R.; Hideshima T.; Anderson K.C.
Link alla scheda completa:
Link al Full Text:
Pubblicato in: